305 related articles for article (PubMed ID: 37521227)
1. Which is the Ideal JAK Inhibitor for Alopecia Areata - Baricitinib, Tofacitinib, Ritlecitinib or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway.
Sardana K; Bathula S; Khurana A
Indian Dermatol Online J; 2023; 14(4):465-474. PubMed ID: 37521227
[TBL] [Abstract][Full Text] [Related]
2. A Review of JAK Inhibitors for Treatment of Alopecia Areata in the Military Health Care System.
Song CJ; Riley CA; Wilkison BD; Cho S
Mil Med; 2024 Jun; ():. PubMed ID: 38850223
[TBL] [Abstract][Full Text] [Related]
3. A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata.
Dillon KL
Clin Cosmet Investig Dermatol; 2021; 14():691-714. PubMed ID: 34211288
[TBL] [Abstract][Full Text] [Related]
4. The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature.
Crowley EL; Fine SC; Katipunan KK; Gooderham MJ
J Cutan Med Surg; 2019; 23(3):289-297. PubMed ID: 30688081
[TBL] [Abstract][Full Text] [Related]
5. Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review.
Egeberg A; Linsell L; Johansson E; Durand F; Yu G; Vañó-Galván S
Dermatol Ther (Heidelb); 2023 Dec; 13(12):2951-2991. PubMed ID: 37833617
[TBL] [Abstract][Full Text] [Related]
6. An overview of JAK/STAT pathways and JAK inhibition in alopecia areata.
Lensing M; Jabbari A
Front Immunol; 2022; 13():955035. PubMed ID: 36110853
[TBL] [Abstract][Full Text] [Related]
7. Janus kinase inhibitors for alopecia areata: A narrative review.
Haughton RD; Herbert SM; Ji-Xu A; Downing L; Raychaudhuri SP; Maverakis E
Indian J Dermatol Venereol Leprol; 2023; 89(6):799-806. PubMed ID: 37436019
[TBL] [Abstract][Full Text] [Related]
8. The Effect of JAK Inhibitor on the Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Restoration in Human Dermal Papilla Cells.
Kim JE; Lee YJ; Park HR; Lee DG; Jeong KH; Kang H
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32698510
[TBL] [Abstract][Full Text] [Related]
9. Ritlecitinib: an investigational drug for the treatment of moderate to severe alopecia areata.
Eisman S; Sinclair R
Expert Opin Investig Drugs; 2021 Dec; 30(12):1169-1174. PubMed ID: 34826225
[TBL] [Abstract][Full Text] [Related]
10. A Real-World Study of Steroid-Free Monotherapy with Tofacitinib in Severe and Therapy-Recalcitrant Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Cases: A Retrospective Analysis.
Sharath S; Sardana K; Khurana A
Indian Dermatol Online J; 2024; 15(1):49-54. PubMed ID: 38282998
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata.
Dai Z; Chen J; Chang Y; Christiano AM
JCI Insight; 2021 Apr; 6(7):. PubMed ID: 33830087
[TBL] [Abstract][Full Text] [Related]
12. Janus kinase inhibitors for alopecia areata.
King BA; Craiglow BG
J Am Acad Dermatol; 2023 Aug; 89(2S):S29-S32. PubMed ID: 37591562
[TBL] [Abstract][Full Text] [Related]
13. Induction of T cell exhaustion by JAK1/3 inhibition in the treatment of alopecia areata.
Dai Z; Sezin T; Chang Y; Lee EY; Wang EHC; Christiano AM
Front Immunol; 2022; 13():955038. PubMed ID: 36203601
[TBL] [Abstract][Full Text] [Related]
14. Emerging drugs for the treatment of alopecia areata.
Ramírez-Marín HA; Tosti A
Expert Opin Emerg Drugs; 2022 Dec; 27(4):379-387. PubMed ID: 36408593
[TBL] [Abstract][Full Text] [Related]
15. Role of janus kinase inhibitors in the treatment of alopecia areata.
Triyangkulsri K; Suchonwanit P
Drug Des Devel Ther; 2018; 12():2323-2335. PubMed ID: 30100707
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis.
Wei D; Chen Y; Shen Y; Xie B; Song X
Front Immunol; 2023; 14():1152513. PubMed ID: 37138884
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata.
Ramírez-Marín HA; Tosti A
Drug Des Devel Ther; 2022; 16():363-374. PubMed ID: 35210753
[TBL] [Abstract][Full Text] [Related]
18. Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib-A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata.
Kołcz K; Żychowska M; Sawińska E; Reich A
Dermatol Ther (Heidelb); 2023 Mar; 13(3):843-856. PubMed ID: 36639612
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2).
Kwon O; Senna MM; Sinclair R; Ito T; Dutronc Y; Lin CY; Yu G; Chiasserini C; McCollam J; Wu WS; King B
Am J Clin Dermatol; 2023 May; 24(3):443-451. PubMed ID: 36855020
[TBL] [Abstract][Full Text] [Related]
20. Baricitinib for the Treatment of Alopecia Areata.
Freitas E; Guttman-Yassky E; Torres T
Drugs; 2023 Jun; 83(9):761-770. PubMed ID: 37195491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
